News
Brixton Biosciences Receives $2M NIH HEAL Initiative Grant to Drive Drug-Free Pain Relief Innovations
CAMBRIDGE, Massachusetts, October 24, 2024 – Brixton Biosciences, a clinical-stage life sciences company, today announced it has been awarded first-year funding of a $2 million grant from the National Institutes of Health (NIH) through the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®. The grant (No. R44AR084998) will support Brixton's ongoing development of Neural Ice™, an injectable, drug-free pain management technology designed to provide long-lasting relief from chronic and post-operative pain. This funding is part of the NIH's efforts to address the opioid crisis by advancing scientific solutions that reduce reliance on opioids for pain treatment.
Read more...
Brixton Biosciences' Neural Ice™ Therapy granted Breakthrough Device designation by the FDA
CAMBRIDGE, Massachusetts, Oct. 25, 2023 – Brixton Biosciences, a clinical-stage life sciences company developing novel therapies for chronic and acute pain, is delighted to announce that its groundbreaking Neural Ice™ Therapy has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
Read more...
Brixton Biosciences Announces $35M in Series B Funding to Advance Novel Technology for the Treatment of Pain
CAMBRIDGE, Massachusetts, May 14, 2024 – Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, today announced that it closed a Series B funding round of $35M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures, PV Capital Management, and Catalyst Health Ventures.
Read more...
